Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Pediatric Brain Tumors Market Size Shifted, And What Is the Outlook Through 2034?

Over recent years, there has been a robust growth in the pediatric brain tumors market size. The market projection is estimated to surge from $1.3 billion in 2024 to $1.4 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.0%. The notable expansion during the historic period can be credited to factors such as the rising cases of pediatric brain tumors, the emergence of strong economies, increased funding in research and development, and an enhanced demand for diagnostic technology. Moreover, there has been a worldwide increase in pediatric tumor cases.

The market for pediatric brain tumors is predicted to experience substantial growth in the coming years, reaching a size of $1.81 billion in 2029, expanding at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth during the forecast period is poised to be driven by precision medicine, molecular profiling, targeted treatments, improvements in healthcare infrastructure, and broader insurance coverage. Emerging trends for the forecast timeframe involve advancements in technologies such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT), alongside the utilization of genetic and molecular profiling, the formulation of targeted therapies, the advent of immunotherapies, and the proliferation of minimally invasive surgical methods.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp

Which Primay Drivers Are Accelerating Growth in the Pediatric Brain Tumors Market?

The pediatric brain tumor market is anticipated to experience robust growth due to the increasing interest in personalized healthcare. This tailor-made approach to treatment and clinical decision-making benefits from a detailed understanding of an individual’s genetic composition, lifestyle, and distinctive healthcare needs. The accelerated push for personalized medicine can be attributed to breakthroughs in genetic studies, sophisticated diagnostic tools, and the promise of better and meticulously aimed treatments. By aligning therapies to a child’s particular tumor characteristics, genetic alterations, and responses, personalized medicine can enhance treatment results and decrease side effects, only attacking the disease and preserving healthy cells. Substantiating this, in February 2024, the US-based Personalized Medicine Coalition noted that, in 2023, the FDA sanctioned 16 novel personalized treatments for patients with rare diseases, a significant increase from the six in the previous year. Thus, this surging demand for personalized healthcare is significantly fueling the expansion of the pediatric brain tumor market.

Which Primary Segments of the Pediatric Brain Tumors Market Are Driving Growth and Industry Transformations?

The pediatric brain tumorsmarket covered in this report is segmented –

1) By Type: Gliomas; Mixed Neuronal-Glial Tumors; Embryonal Tumors; Choroid Plexus Papilloma Or Carcinoma; Tumors Arising From Non-Neuroepithelial Tissue; Meningeal Tumors

2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy

3) By Diagnosis Method: Imaging Techniques; Biopsy; Neurological Exam; Lumbar Puncture

4) By Age Group: Infants; Toddlers; Children; Adolescents

5) By Application: Hospitals And Clinics; Medical Research Centers; Academic Institutes; Other Applications

Subsegments:

1) By Gliomas: Low-Grade Gliomas; High-Grade Gliomas

2) By Mixed Neuronal-Glial Tumors: Gangliogliomas; Dysembryoplastic Neuroepithelial Tumors (DNET)

3) By Embryonal Tumors: Medulloblastoma; Atypical Teratoid Rhabdoid Tumor (ATRT); Primitive Neuroectodermal Tumors (PNET)

4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma; Choroid Plexus Carcinoma

5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma; Ewing’s Sarcoma

6) By Meningeal Tumors: Meningiomas; Hemangiopericytomas

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21248&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Pediatric Brain Tumors Market?# Market?

North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Pediatric Brain Tumors Industry Dynamics?

Leading corporations in the pediatric brain tumors market are concentrating on producing advanced therapy options like type II RAF inhibitors to boost targeted treatments and improve the outcomes for patients. RAF kinases, particularly those with mutations that fuel tumor growth, are the main focus of these specialized therapies known as Type II RAF inhibitors. These inhibitors are tailored to inhibit the irregular RAF protein structures present in some pediatric low-grade glioma (pLGG) subtypes, effectively barricading faulty signaling routes that lead to tumor cell growth and endurance. Day One Biopharmaceuticals, a biotech firm based in the US, declared in April 2024 that the U.S. Food and Drug Administration (FDA) has given accelerated approval for OJEMDA (tovorafenib), a treatment for recurrent or stubborn pediatric low-grade glioma (pLGG) in patients six months and older with particular BRAF alterations. This acknowledgment sets OJEMDA as the inaugural FDA-endorsed treatment that targets BRAF fusions or mutations in this patient group. The approval comes as a result of an overall response rate of 51% in the FIREFLY-1 clinical trial, which evaluated the drug’s effectiveness in this instance. This drug is particularly aimed at pediatric patients whose brain tumors have not reacted to past therapies.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report

What Parameters Are Used to Define the Pediatric Brain Tumors Market?

Pediatric brain tumors are abnormal growths of cells in the brain or central nervous system (CNS) of children. These tumors can be benign (non-cancerous) or malignant (cancerous) and can originate in different parts of the brain or spinal cord. The goal of treatment is to shrink or remove the tumor, relieve symptoms, and preserve cognitive and motor functions, ensuring the child’s long-term health and development.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21248

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model